StreetInsider.com News Articles

Form 4 MeiraGTx Holdings plc For: Oct 20 Filed by: Giroux Richard

Tue, 20 Oct 2026 20:57:00 -0400

si-local-file:///var/storage/secattach/20261020/27211623.html

Form 144 MeiraGTx Holdings plc Filed by: Giroux Richard

Tue, 20 Oct 2026 20:57:00 -0400

si-local-file:///var/storage/secattach/20261020/27211621.html

Form 4 MeiraGTx Holdings plc For: Oct 06 Filed by: Naylor Stuart

Tue, 06 Oct 2026 20:53:00 -0400

si-local-file:///var/storage/secattach/20261006/27156681.html

Form 144 MeiraGTx Holdings plc Filed by: Naylor Stuart

Tue, 06 Oct 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20261006/27155785.html

Form 4 MeiraGTx Holdings plc For: Sep 23 Filed by: SEBULSKY ALAN

Mon, 28 Sep 2026 11:50:00 -0400

si-local-file:///var/storage/secattach/20260928/27112142.html

Form 4 MeiraGTx Holdings plc For: Sep 23 Filed by: SEBULSKY ALAN

Thu, 24 Sep 2026 21:06:00 -0400

si-local-file:///var/storage/secattach/20260924/27103265.html

Form 3 MeiraGTx Holdings plc For: Sep 23 Filed by: SEBULSKY ALAN

Thu, 24 Sep 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260924/27103262.html

Goldman Sachs Starts MeiraGTx Holdings plc (MGTX) at Neutral

Thu, 24 Sep 2026 02:53:44 -0400

Goldman Sachs analyst Andrea Newkirk initiates coverage on MeiraGTx Holdings plc (NASDAQ: MGTX) with a Neutral rating and a price target of $16.00.

The analyst comments: "MGTX is a clinical-stage company leveraging low-dose gene therapies for inherited retinal diseases (lead asset bota-vec for X-linked retinitis pigmentosa (XLRP) and LLY-partnered AAV-AIPL1 for LCA4 congenital blindness, where regulatory packages are being compiled), radiation-induced xerostomia (Ph2 AAV2-hAQP1 AQUAx2 data in 2Q27), and Parkinson's disease (Ph3 AAV-GAD trial to be initiated shortly via joint venture Reogen). For the two wholly-owned programs, bota-vec and AAV2-hAQP1, on the former, we see a convincing value proposition that is

Goldman Sachs Starts MeiraGTx Holdings plc (MGTX) at Neutral

Thu, 24 Sep 2026 02:53:44 -0400

Goldman Sachs analyst Andrea Newkirk initiates coverage on MeiraGTx Holdings plc (NASDAQ: MGTX) with a Neutral rating and a price target of $16.00.

Raymond James: 'we still are encouraged by this near-term opportunity for MGTX'

Wed, 23 Sep 2026 10:10:50 -0400

Raymond James: 'we still are encouraged by this near-term opportunity for MGTX'.

The analyst comments "We remain Strong Buy rated on MGTX shares following the release of topline pivotal data for Beacon Therapeutics’ (private) gene therapy laru-zova in XLRP, which we think provides important readthrough to MGTX’s similar gene therapy bota-vec. Recall MGTX reacquired the rights to bota-vec from JNJ after the pivotal LUMEOS trial failed to meet the primary endpoint of the visual mobility assessment, but we have argued that we still see a reasonable regulatory path forward based on the strength of multiple secondary endpoints including low level visual

Form 8-K MeiraGTx Holdings plc For: Sep 22

Wed, 23 Sep 2026 08:13:00 -0400

si-local-file:///var/storage/secattach/20260923/27093657.html

MeiraGTx names Alan Sebulsky to its board of directors

Wed, 23 Sep 2026 08:00:34 -0400

MeiraGTx Holdings plc (NASDAQ: MGTX) has appointed Alan M. Sebulsky to its board of directors, the clinical-stage genetic medicines company announced.

Sebulsky brings more than 40 years of experience in public company investment, financial strategy, and portfolio management. He most recently served as partner and portfolio manager at Adage Capital Management for 14 years, where he oversaw a biopharmaceutical portfolio with over $2 billion in assets.

Sebulsky founded Apothecary Capital, an asset management firm focused on healthcare and biopharmaceutical investments, and reestablished the firm in April 2026, where he currently serves as managing member.

He currently serves on the board of Parabilis Medicines,

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

Wed, 23 Sep 2026 08:00:00 -0400

LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.

Mr. Sebulsky is a veteran healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in public company investment, financial strategy, portfolio evaluation and growth, and board leadership. Mr. Sebulsky most recently served as Partner and Portfolio Manager at Adage Capital Management for the past 14 years, where he led a team overseeing a diversified biopharmaceutical portfolio with over

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

Wed, 23 Sep 2026 08:00:00 -0400

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

Wed, 26 Aug 2026 10:49:00 -0400

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.
GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.
Complete responses were observed in all but one organ

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

Wed, 26 Aug 2026 10:49:00 -0400

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.
GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.
Complete responses were observed in all but one organ

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

Wed, 26 Aug 2026 10:49:00 -0400

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.
GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.
Complete responses were observed in all but one organ

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide

Wed, 26 Aug 2026 10:49:00 -0400

GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy.
GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
Failure-free survival (FFS) was 83.9% at 24 weeks and reached 89.4% at 400 mg (78.6% at 200 mg); this FFS also exceeds published 6-month FFS probabilities for all approved steroid-refractory cGvHD therapies.
Complete responses were observed in all but one organ

Form 4 MeiraGTx Holdings plc For: Aug 18 Filed by: Forbes Alexandria

Tue, 18 Aug 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26946064.html

Form 4 MeiraGTx Holdings plc For: Aug 18 Filed by: Forbes Alexandria

Tue, 18 Aug 2026 21:03:00 -0400

si-local-file:///var/storage/secattach/20260818/26946064.html

Form 144 MeiraGTx Holdings plc Filed by: Forbes Alexandria

Tue, 18 Aug 2026 21:02:00 -0400

si-local-file:///var/storage/secattach/20260818/26946062.html

Form 144 MeiraGTx Holdings plc Filed by: Forbes Alexandria

Tue, 18 Aug 2026 21:02:00 -0400

si-local-file:///var/storage/secattach/20260818/26946062.html

Form SCHEDULE 13G/A MeiraGTx Holdings plc Filed by: Rubric Capital Management LP

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930350.html

Form SCHEDULE 13G/A MeiraGTx Holdings plc Filed by: Rubric Capital Management LP

Fri, 14 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26930350.html

MeiraGTx Holdings plc (MGTX) PT Raised to $27 at RBC Capital

Fri, 14 Aug 2026 08:41:59 -0400

RBC Capital analyst Lisa Walter raised the price target on MeiraGTx Holdings plc (NASDAQ: MGTX) to $27.00 (from $26.00) while maintaining a Outperform rating.